|
Security
Type
|
Security Class Title
|
Fee Calculation Rule
|
|
Amount
to be
Registered(1)
|
|
Proposed
Maximum
Offering Price
per Share(2)
|
|
Maximum
Aggregate
Offering Price
|
Fee Rate
|
|
Amount of
Registration
Fee
|
||||||
|
Equity
|
Common Shares, no par value per share
|
Other (2)
|
|
14,167,855
|
|
$8.17
|
|
$115,751,376
|
$0.0000927
|
|
$10,731
|
||||||
|
Total Offering Amounts
|
|
|
|
$115,751,376
|
|
—
|
|||||||||||
|
Total Fees Previously Paid
|
—
|
||||||||||||||||
|
Total Fee Offsets
|
—
|
||||||||||||||||
|
Net Fee Due
|
$10,731
|
||||||||||||||||
|
|
|||||||||||||||||
|
|
|||||||||||||||||
|
(1)
|
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional common shares, no par value per share (“common shares”) of
Abcellera Biologics Inc. (the “Registrant”) which become issuable under the Registrant’s 2020 Share Option and Incentive Plan (the “2020 Plan”) by reason of any share dividend, share split, recapitalization or any other similar transaction
effected without the receipt of consideration which results in an increase in the number of our outstanding common shares.
|
||||||||||||||||
|
(2)
|
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, and based on $8.17, the average of the high and low sale prices of the Registrant’s common shares as reported
on the Nasdaq Stock Market on February 24, 2022.
|
||||||||||||||||
|
(3)
|
Represents an automatic increase to the number of shares available for issuance under the 2020 Plan, in accordance with the automatic annual increase provision of the 2020 Plan, effective as of January 1, 2022. Shares available for
issuance under the 2020 Plan were previously registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission on December 15, 2020 (File No. 333-251341).
|
||||||||||||||||